INNOVATE Corp's MediBeacon Receives $10M In Amended Agreements With Huadong Medicine
INNOVATE Corp's MediBeacon Receives $10M In Amended Agreements With Huadong Medicine
Innovate Corp的MediBeacon在与华东医药的修订协议中获得1000万美元
MediBeacon Inc., a portfolio company within the Pansend Life Sciences segment of INNOVATE Corp. (NYSE:VATE), today announced amendments to its commercial partnership with Huadong Medicine Co., Ltd., which trades on the Shenzhen Stock Exchange. MediBeacon is a medical technology company specializing in the advances of fluorescent tracer agents and transdermal measurement.
MediBeacon公司是Innovate Corp.(纽约证券交易所代码：VATE)旗下Pansend生命科学部门的投资组合公司，该公司今天宣布修改其与深圳证券交易所上市的华东医药股份有限公司的商业合作伙伴关系。MediBeacon是一家医疗技术公司，专门从事荧光示踪剂和透皮测量的进展。